SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.0B
Q4 2023
Positions
52
Filings on Record
27
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Boxer Capital, LLC reported $2.0B in U.S.-listed holdings across 52 positions for Q4 2023.

Its largest position, MRTXEUR, represents 9.4% of the portfolio.

Compared with Q3 2023, the fund opened 4 new positions and exited 25.

Portfolio Metrics

Turnover
+20.7%
vs prior filed quarter
Top-10 Concentration
+57.1%
share of reported value
Largest Position
+9.4%
Mirati Therapeutics
New / Exited
4 / 25
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 81.6%ADR: 10.1%Other: 8.3%Equity WRT: 0.0%
  • Common Stock · 81.6% · $1.6B
  • ADR · 10.1% · $203M
  • Other · 8.3% · $166M
  • Equity WRT · 0.0% · $17,333

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ARVNArvinas IncNEW+608.6K608.6K+$25M$25M
GPCRStructure Therapeutics IncNEW+400.0K400.0K+$16M$16M
NKTXNkarta IncNEW+1.44M1.44M+$10M$10M
SYRESpyre Therapeutics IncNEW+250.0K250.0K+$5M$5M
AMLXAmylyx Pharmaceuticals IncSOLD OUT−2.08M0−$38M$0
SPDR Ser TrSOLD OUT−500.0K0−$37M$0
VTYXUSDVentyx Biosciences IncSOLD OUT−850.0K0−$30M$0
AM6Amicus Therapeutics IncSOLD OUT−2.33M0−$28M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMirati Therapeutics Inchistory →COM9.37%$188M3.20M
2CYTKCytokinetics Inchistory →COM NEW8.74%$175M2.10M
3SWTXUSDSpringworks Therapeutics Inchistory →COM6.22%$125M3.42M
4RVMDRevolution Medicines Inchistory →COM6.12%$123M4.28M
5APLSUSDApellis Pharmaceuticals Inchistory →COM5.15%$103M1.73M
6ONCBeiGene Ltdhistory →SPONSORED ADR4.49%$90M500.0K
7TYRATyra Biosciences Inchistory →COM4.45%$89M6.45M
8IMGNEURImmunoGen Inchistory →COM4.38%$88M2.96M
9NUVLNuvalent Inchistory →COM4.11%$82M1.12M
10TNGXTango Therapeutics Inchistory →COM4.05%$81M8.20M
11Karuna Therapeutics IncCOM3.94%$79M250.0K
12IDYAIdeaya Biosciences Inchistory →COM3.91%$78M2.20M
13SRPTSarepta Therapeutics Inchistory →COM3.12%$63M650.0K
14ARGXArgenx SEhistory →SPONSORED ADR3.03%$61M160.0K
15Merus N VCOM2.60%$52M1.90M
16RCKTRocket Pharmaceuticals Inchistory →COM2.19%$44M1.47M
17IMVTImmunovant Inchistory →COM2.10%$42M1.00M
18AKROAkero Therapeutics Inchistory →COM1.95%$39M1.68M
19LEGNLegend Biotech Corphistory →SPONSORED ADS1.80%$36M600.0K
20AXSMAxsome Therapeutics Inchistory →COM1.59%$32M400.0K
21RCUSArcus Biosciences Inchistory →COM1.53%$31M1.60M
22ANABAnaptysBio Inchistory →COM1.39%$28M1.30M
23XENEXenon Pharmaceuticals Inchistory →COM1.38%$28M600.0K
24ARVNArvinas Inchistory →COM1.25%$25M608.6K
25Prothena Corp PLCSHS1.20%$24M665.0K
264XC1Kalvista Pharmaceuticals Inchistory →COM1.01%$20M1.65M
27RLAYRelay Therapeutics Inchistory →COM1.00%$20M1.82M
282662247DiTeos Therapeutics Inchistory →COM0.98%$20M1.80M
29DAWNGBXDay One Biopharmaceuticals Ihistory →COM0.87%$17M1.19M
30GPCRStructure Therapeutics Inchistory →SPONSORED ADS0.81%$16M400.0K
31ORICOric Pharmaceuticals Inchistory →COM0.79%$16M1.73M
32IOVAIovance Biotherapeutics Inchistory →COM0.57%$11M1.40M
33PRLDPrelude Therapeutics Inchistory →COM0.55%$11M2.57M
34RNAGBPAvidity Biosciences Inchistory →COM0.51%$10M1.12M
35NKTXNkarta IncCOM0.47%$10M1.44M
36ELVNEnliven Therapeutics IncCOM0.45%$9M646.1K
37Third Harmonic Bio IncCOM0.41%$8M750.0K
38ZNTLZentalis Pharmaceuticals IncCOM0.34%$7M450.0K
39GONGeron CorpCOM0.32%$6M3.00M
40SYRESpyre Therapeutics IncCOM NEW0.27%$5M250.0K
41OBIOOrchestra Biomed Hldgs IncCOM0.11%$2M238.2K
42FATEFate Therapeutics IncCOM0.09%$2M500.0K
43KODKodiak Sciences IncCOM0.09%$2M600.0K
44BCABGBPBioAtla IncCOM0.08%$2M686.3K
45BDTXBlack Diamond Therapeutics ICOM0.07%$1M506.0K
46Rain Oncology IncCOM0.07%$1M1.15M
47MISTMilestone Pharmaceuticals InCOM0.03%$516,042309.0K
48DBV Technologies S ASPONSORED ADR0.02%$476,400500.0K
49TARAProtara Therapeutics IncCOM STK0.02%$392,322209.2K
50Atreca IncCL A COM0.01%$290,7082.20M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.